A recent phase III study revealed a benefit with pacritinib for patients with myelofibrosis and thrombocytopenia who have experienced treatment failure with previous therapies.
Original Article: Pacritinib May Benefit Patients with Myelofibrosis and Thrombocytopenia
NEXT ARTICLE